1.74
+0.01(+0.58%)
Currency In USD
| Previous Close | 1.73 |
| Open | 1.85 |
| Day High | 1.85 |
| Day Low | 1.66 |
| 52-Week High | 176 |
| 52-Week Low | 1.61 |
| Volume | 1.14M |
| Average Volume | 2.71M |
| Market Cap | 5.35M |
| PE | -0.02 |
| EPS | -88.92 |
| Moving Average 50 Days | 2.38 |
| Moving Average 200 Days | 58.47 |
| Change | 0.01 |
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
Lead asset EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.Northstrive Biosciences Inc. is preparing the necessa
PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies
GlobeNewswire Inc.
Jan 31, 2025 3:33 PM GMT
NEWPORT BEACH, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce that its operating investment division, PMGC Capital LLC, has begun building its portfolio with strategic in
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
GlobeNewswire Inc.
Jan 30, 2025 1:00 PM GMT
Groundbreaking research to evaluate the effects of EL-32, alone and in combination with semaglutide, on glycemic control and body composition in diet-induced obese mice.EL-32 is an engineered probiotic expressing dual myostatin & activin-A, focusing